Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ

940 posts

Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ banner
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ

Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ

@KidneyCancerJ

An International, Scientific, Peer-reviewed Journal (ISSN 1933-0863) for latest advances & quality research in Kidney Cancers published by https://t.co/HCXkWc9qFE

USA Katılım Kasım 2019
5K Takip Edilen1.4K Takipçiler
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Cristiane D Bergerot, PhD, FASCO
Cristiane D Bergerot, PhD, FASCO@crisbergerot·
Development & validation of a Computational Histology AI (CHAI) prognostic biomarker in RCC AI-derived digital pathology features predicted PFS, DSS, and OS; offering potential to refine risk stratification beyond traditional clinicopathologic models #GU26 @montypal
Cristiane D Bergerot, PhD, FASCO tweet media
English
2
5
15
797
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
Terrific presentation from @DrChoueiri - another sea change in adjuvant treatment. If we see survival, a very strong consideration for most patients in this setting. Even now, worth a discussion … of note, door is still open to adjuvant trials like #STRIKE (@BradMcG04) & ISTs that are pembro-based. Super proud of see @cityofhope #urology superstar @WesleyYipMD showcased in this practice-changing trial at #GU26! @SoCalYuman @ClaytonLauMD @COHurol @DrMvandenBrink @cityofhopeoc @CityofHopeSurg
Martín Angel@Martin_AngelMD

🆕adjuvant combo for #RCC : LITESPARK-022 #GU26 DFS: HR: 0.72‼️ OS: inmature data..... but comparator arm was THE most effective active treatment available. @DrChoueiri @tompowles1 @BourlonMaite @ASCO

English
3
21
58
6.3K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
LITESPARK-011 | Phase III | #ASCOGU26 #GU26 Belzutifan + Lenvatinib vs Cabozantinib in advanced clear-cell RCC post anti–PD-(L)1 A pivotal study redefining the post-IO VEGFR-TKI landscape. @motzermd @OncoAlert 🔬 Primary endpoints • Superior PFS vs cabozantinib • Higher ORR • OS numerically favored but not statistically significant (final analysis pending) 📊 Key efficacy data • mPFS: 14.6 vs 10.0 mo (HR 0.74) • ORR: 52% vs 40% • mOS: 34.9 vs 27.6 mo (NS) 🧠 Why this matters • First phase III of a HIF-2α inhibitor + VEGFR-TKI • First phase III RCC study post–PD-(L)1 showing superiority over a contemporary VEGFR-TKI • Expands mechanistic targeting beyond pure VEGF inhibition 🛡 Safety • Profile consistent with known individual drugs • No unexpected signals • QoL and symptom deterioration similar between arms 🎯 Big picture Belzutifan + lenvatinib addresses a clear unmet need in IO-pretreated RCC and may represent a new standard option in this setting. Kidney cancer continues to evolve toward rational biology-driven combinations.
Dra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet media
English
1
9
14
3K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Alan Tan
Alan Tan@alantanmd·
BREAKING at #GU26: The Phase 3 LITESPARK-022 study meets its primary endpoint. Adjuvant pembrolizumab + belzutifan significantly improved Disease-Free Survival (DFS) vs pembro alone for clear cell RCC at risk of recurrence: 🔹 HR: 0.72 (95% CI, 0.59–0.87) 🔹 P = 0.0003 🔹 OS data still immature (HR 0.78) Safety: Anemia was the most common AE in the combo arm (84%). #KidneyCancer #RCC #OncTwitter
Alan Tan tweet mediaAlan Tan tweet mediaAlan Tan tweet mediaAlan Tan tweet media
English
1
4
7
438
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Daniel Heng
Daniel Heng@DrDanielHeng·
I’m so proud of @DrChoueiri! Here is LITESPARK022 which is the first combination IO in adjuvant @kidneycancer. DFS positive and OS immature. Looking forward to more OS, QOL endpoints and subsequent therapy. Largest trial in IO adjuvant RCC. #oncoalert #GU26 #Toniiscool
Daniel Heng tweet mediaDaniel Heng tweet mediaDaniel Heng tweet mediaDaniel Heng tweet media
English
0
12
32
1.5K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Roberto Iacovelli
Roberto Iacovelli@DrIacovelli·
So proud of these young colleagues I have the privilege to work with. Come to see and discuss our data after adjuvant IO in RCC, trial in progress & concurrence of mutations in PCa presented at #GU26. Thanks to Daniela Arduini, Paola Troisi, Denis Occhipinti. @OncoAlert @Unicatt
Roberto Iacovelli tweet mediaRoberto Iacovelli tweet mediaRoberto Iacovelli tweet mediaRoberto Iacovelli tweet media
English
0
9
25
1.3K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Michael Serzan, MD
Michael Serzan, MD@MikeSerzanMD·
🗣️Innovation in RCC #GU26 👉Dr @lalaniMD presenting phase 2 #CYTOSHRINK utilizing primary SBRT w/ Nivo/Ipi for pts with I/P risk ccRCC. 👥 (n=67) randomized 2:1 Nivo/Ipi +/- SBRT 💉C1 Nivo/Ipi ⚡️ SBRT x5 to Primary Kidney Mass 💉C2-4 Nivo/Ipi followed by Nivo maintenance 📊12mo PFS Nivo/Ipi + SBRT: 35% Nivo/Ipi alone: 48% (HR 1.29; 0.69-2.4) 📊ORR Nivo/Ipi + SBRT: 33% Nivo/Ipi alone: 42% 📊18mo OS Nivo/Ipi + SBRT: 59% Nivo/Ipi alone: 70% ⚠️G3 TRAE 23% vs 29% 🔑Key Data underscoring that SBRT to the primary kidney after C1 did not improve outcomes for pt with I/P ccRCC treated with Nivo/Ipi. Patient selection remains critical when incorporating radiation & cytoreductive nephrectomy with systemic therapy. @DrChoueiri @montypal @motzermd @tompowles1 @ChadTangMD @VincentWenxinXu @katy_beckermann @bergsa83 @DrKarineTawagi @drenriquegrande @yekeduz_emre @OncoAlert @OncBrothers @urotoday @Uromigos @kidneycan
Michael Serzan, MD tweet mediaMichael Serzan, MD tweet mediaMichael Serzan, MD tweet mediaMichael Serzan, MD tweet media
Indonesia
1
6
8
523
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
OncoAlert
OncoAlert@OncoAlert·
A Great Start to Day 3⃣ at #GU26 ⛄️ OncoAlert🚨Brings Dr. Toni Choueiri 🇺🇸from the PODIUM in San Francisco to your Screen Presenting LITESPARK-022 Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC) #KidneyCancer ➡️ adj pembro + belz improved DFS🆚 pembro alone ➡️OS immature ➡️Manageable safety; ↑ grade ≥3 AEs ⭐️ Potential new Standard of Care! Dr Choueiri Showing us that no matter the Weather❄️ Science NEVER stops!! @DrChoueiri @motzermd @DrIacovelli @DrYukselUrun @elena_verzoni @tompowles1 @montypal @crisbergerot @DrDanielHeng @apolo_andrea @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @drenriquegrande @BraunMDPhD @cdanicas @brian_rini @AUC3_Official @nataliagandur @MarcMachaalani @Mustafajsalehmd @NazliDizman @DrYukselUrun @yekeduz_emre @WeiweiBian @ReneeSaliby @eddy_saad @Clara__Steiner @marc_eid @pablombarrios @WDKhatoun @Jad_El_Masri @lilli_ash @RashadNawfal @RazaneHChehade @elioibrahim8 @NafehGaelle @shaye_carver @zeyun_lu @SylvanBacaLab
English
0
21
31
4.5K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Jun Gong
Jun Gong@jgong15·
Dr. McDermott @BIDMChealth PhI/II LITESPARK-024 trial of belzutifan + palbociclib in adv #ccRCC (>2 prior lines) ➡️ at MTD 125 mg palbo, ORR 21.1%, median PFS 9.1 mos, most common G>3 AE being neutropenia @OncoAlert #GU26
Jun Gong tweet mediaJun Gong tweet mediaJun Gong tweet mediaJun Gong tweet media
English
0
9
15
654
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri·
Comprehensive presentation by Dr. @HHammersMD spotlighting emerging targets in RCC: From HIF-2α inhibition to mRNA vaccines, CAR-T cells, and bispecific antibodies. The field is evolving fast, with so much on the horizon. #GU26 @OncoAlert @OncBrothers
Toni Choueiri, MD tweet mediaToni Choueiri, MD tweet mediaToni Choueiri, MD tweet mediaToni Choueiri, MD tweet media
English
2
21
32
2.2K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Dan George
Dan George@Daniel_J_George·
Pts achieving pCR following ICI-based therapy for RCC exhibit more favorable onc outcomes vs pts with residual disease. Long term surveillance still important. @alirezaghoreifi @DukeCancer #GU26 @MRHarrisonMD
English
1
7
26
3.3K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Matt Campbell MD, MS
Matt Campbell MD, MS@DocMattCampbell·
Incredible start at Saturday at #GU26 LITESPARK 011 presented by Dr Motzer finding Ph3 superiority in PFS of Len/bel vs cabo benefit appears to appear late, 30% fall off early in both arms, impressive durability for responders in Len/bel
Matt Campbell MD, MS tweet mediaMatt Campbell MD, MS tweet mediaMatt Campbell MD, MS tweet mediaMatt Campbell MD, MS tweet media
English
0
8
26
1.4K
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ retweetledi
Tom Powles
Tom Powles@tompowles1·
R3 LITESPARK-022: Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab for Clear Cell Renal Cell Carcinoma #GU26 showed significantly delayed DFS HR 0.72 (95% CI, 0.59–0.87) active across all subgroups. Immature OS (30 mnth OS 93% CDs 96%). ⬆️ Anaemia fatigue and transaminitis but only 4% discontinuation rate for belzutifan. The shape of the DFS curve and early OS trending the right way looks like initial analysis of KN564 and we know where that ended, making pem/bel attractive. @OncoAlert @DrChoueiri
Tom Powles tweet mediaTom Powles tweet mediaTom Powles tweet mediaTom Powles tweet media
English
1
36
69
6K